Recommended Adult Immunization Schedule – United States, 2015

Note: These recommendations must be read with the footnotes that follow containing number of doses, intervals between doses, and other important information.

Figure 1. Recommended adult immunization schedule, by vaccine and age group

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>19–21 years</th>
<th>22–26 years</th>
<th>27–49 years</th>
<th>50–59 years</th>
<th>60–64 years</th>
<th>≥65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Td/Tdap**                                            | 1 dose annually | Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs
| Varicella**                                          |             |             |             |             |             |          |
| Human papillomavirus (HPV) Female**                  | 2 doses     |             |             |             |             |          |
| Human papillomavirus (HPV) Male**                    | 3 doses     |             |             |             |             |          |
| Zoster**                                             |             |             |             |             |             | 1 dose   |
| Measles, mumps, rubella (MMR)**                      | 1 or 2 doses|             |             |             |             |          |
| Pneumococcal 13-valent conjugate (PCV13)**           |             |             |             |             |             | 1-time dose |
| Pneumococcal polysaccharide (PPSV23)                 |             |             |             |             |             |          |
| Meningococcal**                                     |             |             |             |             |             | 1 or more doses |
| Hepatitis A**                                        |             |             |             |             |             | 2 doses   |
| Hepatitis B**                                        |             |             |             |             |             | 3 doses   |
| Haemophilus influenzae type b (Hib)****              |             |             |             |             |             | 1 or 3 doses |

Figure 2. Vaccines that might be indicated for adults based on medical and other indications

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Pregnancy</th>
<th>Immuno-compromising conditions (excluding human immunodeficiency virus [HIV])</th>
<th>HIV Infection CD4+ T lymphocyte count&lt;200 cells/μL</th>
<th>&gt;200 cells/μL</th>
<th>Men who have sex with men (MSM)</th>
<th>Kidney failure, end-stage renal disease, receipt of hemodialysis</th>
<th>Heart disease, chronic lung disease, chronic alcoholism</th>
<th>Asplenia (including elective splenectomy and persistent complement component deficiencies)</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
<th>Healthcare personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td/Tdap**</td>
<td></td>
<td>1 dose IIV annually</td>
<td>1 dose IIV or LAIV annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella**</td>
<td></td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV Female**</td>
<td></td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV Male**</td>
<td></td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 21 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster**</td>
<td></td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR**</td>
<td></td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPSV23**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No recommendation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Covered by the Vaccine Injury Compensation Program.

For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection; zoster vaccine recommended regardless of prior episode of zoster

Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indication)

No recommendation

These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of February 1, 2015. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers’ package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
1. Additional Information

- Additional guidance for the use of the vaccines described in this supplement is available at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- Information on recommendations when vaccination status is unknown and other general immunization information can be found in the General Recommendations on Immunization at www.cdc.gov/mmwr/preview/mmwrhtml/r6002a1.htm.
- Information on travel vaccine requirements and recommendations (e.g., for hepatitis A and B, meningococcal, and other vaccines) is available at wwwnc.cdc.gov/travel/destinations/list.
- Additional information and resources regarding vaccine administration for pregnant women can be found at www.cdc.gov/vaccines/adults/rec-vac/pregnant.html.

2. Influenza vaccination.

- Annual vaccination against influenza is recommended for all persons age 6 months or older. Person's age 6 months and older, including pregnant women and persons with hives-only allergy to eggs, can receive the inactivated influenza vaccine (IIV). An age-appropriate IIV formulation should be used.
- Adults age 18 years or older can receive the recombinant influenza vaccine (RIV) (Flublok). RIV does not contain any egg protein and can be given to age-appropriate persons with egg allergy or any severity.
- Healthy, nonpregnant persons age 2 through 49 years without high-risk medical conditions can receive either intranasally administered live, attenuated influenza vaccine (LAIV) (Flumist), or IIV.
- Healthcare personnel who care for severely immunocompromised persons who require care in a protected environment should receive IIV or RIV; healthcare personnel who receive LAIV should avoid providing care for severely immunosuppressed persons for 7 days after vaccination.
- The intramuscularly or intradermally administered IIV are options for adults age 18 through 64 years.
- Adults age 65 years or older can receive the standard-dose IIV or the high-dose IIV (Fluzone High-Dose).
- A list of currently available influenza vaccines can be found at www.cdc.gov/vaccines/hcp/acip-recs/index.html.

3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination.

- Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy (preferably during 27 to 36 weeks' gestation), regardless of interval since prior Td or Tdap vaccination.
- Persons age 11 years or older who have not received Tdap vaccine or for whom vaccine status is uncertain should receive a dose of Tdap following by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. Tdap can be administered regardless of interval since the most recent tetanus or diphtheria toxoid-containing vaccine.
- Adults with an unknown or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series including a Tdap dose.
- For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third dose 6 to 12 months after the second.
- For incompletely vaccinated (i.e., less than 3 doses) adults, administer remaining doses.
- Refer to the ACIP statement for recommendations for administering Td/Tdap as prophylaxis in wound management (see footnote 1).

4. Varicella vaccination.

- All adults without evidence of immunity to varicella (as defined below) should receive 2 doses of single-antigen varicella vaccine or a second dose if they have received only 1 dose.
- Vaccination should be emphasized for those who have close contact with persons at high risk for severe disease (e.g., healthcare personnel and family contacts of persons with immunocompromising conditions) or are at high risk for exposure to varicella (e.g., teachers; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers).
- Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility. The second dose should be administered 4 to 8 weeks after the first dose.
- Evidence of immunity to varicella in adults includes any of the following: 1) documentation of 2 doses of varicella vaccine at least 4 weeks apart; 2) U.S.-born before 1980, except healthcare personnel and pregnant women; 3) history of varicella based on diagnosis or verification of varicella disease by a healthcare provider; 4) history of herpes zoster based on diagnosis or verification of herpes zoster disease by a healthcare provider; or 5) laboratory evidence of immunity or laboratory confirmation of disease.

5. Human papillomavirus (HPV) vaccination.

- Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
- For females, either HPV4 or HPV2 is recommended in a 3-dose series for routine vaccination at age 11 or 12 years, and for those age 13 through 26 years, if not previously vaccinated.
- For males, HPV4 is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those age 13 through 21 years, if not previously vaccinated. Males age 22 through 26 years may be vaccinated.
- HPV4 is recommended for men who have sex with men through age 26 years for those who did not get any or all doses when they were younger.
- Vaccination is recommended for immunocompromised persons (including those with HIV infection) through age 26 years for those who did not get any or all doses when they were younger.
- A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose should be administrated 4 to 8 weeks (minimum interval of 4 weeks) after the first dose; the third dose should be administrated 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of at least 12 weeks).
- HPV vaccines are not recommended for use in pregnant women. However, pregnancy testing is not needed before vaccination. If a woman is found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the 3-dose series should be delayed until completion or termination of pregnancy.

6. Zoster vaccination.

- A single dose of zoster vaccine is recommended for adults age 60 years or older regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons age 50 years or older, ACIP recommends that vaccination begin at age 60 years.
- Persons age 60 years and older with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication, such as pregnancy or severe immunodeficiency.

7. Measles, mumps, rubella (MMR) vaccination.

- Adults born before 1957 are generally considered immune to measles and mumps. All adults born in 1957 or later should have documentation of 1 or more doses of MMR vaccine unless they have a medical contraindication to the vaccine or laboratory evidence of immunity to each of the three diseases. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella.
- Measles component: A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who: 1) are students in postsecondary educational institutions, 2) work in a healthcare facility, or 3) plan to travel internationally. Persons who received inactivated (killed) measles vaccine or measles vaccine of unknown type from 1963–1967 should be revaccinated with 2 doses of MMR vaccine.
- Mumps component: A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who: 1) are students in postsecondary educational institution, 2) work in a healthcare facility, or 3) plan to travel internationally. Persons vaccinated before 1979 with either killed mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection (e.g., persons who are working in a healthcare facility) should be considered for revaccination with 2 doses of MMR vaccine.
- Rubella component: For women of childbearing age, regardless of birth year, rubella immunity should be determined. If there is no evidence of immunity, women who are not pregnant should be vaccinated. Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility.
- Healthcare personnel born before 1957: For unvaccinated healthcare personnel born before 1957 who lack laboratory evidence of measles, mumps, and/or rubella immunity or laboratory confirmation of disease, healthcare facilities should consider vaccinating personnel with 2 doses of MMR vaccine at the appropriate interval for measles and mumps or 1 dose of MMR vaccine for rubella.


- General information.
  - When indicated, only a single dose of PCV13 is recommended for adults.
  - No additional PPSV23 is indicated for adults vaccinated with PPSV23 at or after age 65 years.
  - When both PCV13 and PPSV23 are indicated, PCV13 should be administered first; PPSV13 and PPSV23 should not be administered during the same visit.
  - When indicated, PCV13 and PPSV23 should be administered to adults whose pneumococcal vaccination history is incomplete or unknown.
- Adults age 65 years and older who:
  - have not received PCV13 or PPSV23: administer PCV13 followed by a PPSV23 in 6 to 12 months.
  - have not received PCV13 but have received a dose of PPSV23 at age 65 years or older: administer PCV13 at least 1 year after the dose of PPSV23 received at age 65 years or older.
  - have not received PCV13 but have received 1 or more doses of PPSV23 before age 65: administer PCV13 at least 1 year after the most recent PPSV23; administer a dose of PPSV23 6 to 12 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after most recent dose of PPSV23.
  - have received PCV13 but not PPSV23 before age 65 years: administer PPSV23 6 to 12 months after PCV13 or as soon as possible if this time window has passed.

(continued)
– have received PCV13 and 1 or more doses of PPSV23 before age 65 years: administer PPSV23 at 6 to 12 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after the most recent dose of PPSV23.

• Adults age 19 through 64 years with immunocompromising conditions or functional or anatomic asplenia (defined below) who
  – have not received PCV13 or PPSV23: administer PCV13 followed by PPSV23 at least 8 weeks after PCV13; administer a second dose of PPSV23 at least 5 years after the first dose of PPSV23.
  – have not received PCV13 but have received 1 dose of PPSV23: administer PCV13 at least 1 year after the PPSV23; administer a second dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the first dose of PPSV23.
  – have not received PCV13 but have received 2 or more doses of PPSV23: administer PCV13 and at least 1 year after the most recent dose of PPSV23.
  – have received PCV13 but not PPSV23: administer PPSV23 at least 8 weeks after PCV13; administer a second dose of PPSV23 at least 5 years after the first dose of PPSV23.
  – have received PCV13 and 1 dose of PPSV23: administer a second dose of PPSV23 at least 5 years after the first dose of PPSV23.

• Adults age 19 through 64 years who have cerebrospinal fluid leaks or cochlear implants: administer PCV13 followed by PPSV23 at least 8 weeks after PCV13.

• Adults age 19 through 64 years who have chronic heart disease (including congestive heart failure and cardiomyopathies, excluding hypertension), chronic lung disease (including chronic obstructive lung disease, emphysema, and asthma), chronic liver disease (including cirrhosis), alcoholism, or diabetes mellitus: administer PPSV23.

• Adults age 19 through 64 years who smoke cigarettes or reside in nursing homes or long-term care facilities: administer PPSV23.

• Routine pneumococcal vaccination is not recommended for American Indian/Alaska Native or other Native Americans unless they have the indications as above; however, public health authorities may consider recommending the use of pneumococcal vaccines for American Indians/Alaska Natives or other adults who live in areas with increased risk for invasive pneumococcal disease.

• Immunocompromising conditions that are indications for pneumococcal vaccination are: congenital or acquired immunodeficiency (including B- or T-lymphocyte deficiency; complement deficiencies, and phagocytic disorders excluding chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin’s disease, generalized malignancy, multiple myeloma, seroma organ transplant, and iatrogenic immunosuppression (including long-term systemic corticosteroids and radiation therapy for cancer).

• Anatomical or functional asplenia that are indications for pneumococcal vaccination are: sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, and splenectomy. Administer pneumococcal vaccines at least 2 weeks before immunosuppressive therapy or an elective splenectomy, and as soon as possible to adults who are newly diagnosed with asymptomatic or symptomatic HIV infection.

9. Meningococcal vaccination.

• Administer 2 doses of quadrivalent meningococcal conjugate vaccine (MenACWY [Men- actra, Menveo]) at least 2 months apart to adults of all ages with anatomic or functional asplenia or persistent complement component deficiencies. HIV infection is not an indication for routine vaccination with MenACWY. If an HIV-infected person of any age is vaccinated, 2 doses of MenACWY vaccine should be administered at least 2 months apart.

• Administer a single dose of meningococcal vaccine to microbiologists routinely exposed to isolates of Neisseria meningitidis, military recruits, persons at risk during an outbreak attributable to a vaccine serogroup, and persons who travel to or live in countries in which meningococcal disease is epidemic or pandemic.

• First-year college students up through age 21 years who are living in residence halls should be vaccinated if they have not received a dose on or after their 16th birthday.

• MenACWY is preferred for adults with any of the preceding indications who are age 55 years or younger as well as for adults age 56 years or older who a) were vaccinated previously with MenACWY and are recommended for revaccination, or b) for whom multiple doses are anticipated. Meningococcal polysaccharide vaccine (MPSV4 [Menomune]) is preferred for adults age 56 years or older who have not received MenACWY previously and who require a single dose only (e.g., travelers).

• Revaccination with MenACWY every 5 years is recommended for adults previously vaccinated with MenACWY or MPSV4 who remain at increased risk for infection (e.g., adults with anatomic or functional asplenia, persistent complement component deficiencies, or microbiologists).


• Vaccinate any person seeking protection from hepatitis A virus (HAV) infection and persons with any of the following indications:
  – men who have sex with men and persons who use injection or noninjection illicit drugs;
  – persons working with HAV-infected primates or with HAV in a research laboratory setting;

• persons with chronic liver disease and persons who receive clotting factor concentrates;

• persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A; and

• unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity. (See footnote 1 for more information on travel recommendations.) The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.

• Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6 to 12 months (Havrix), 0 or 6 to 16 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinstrix) is used, administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21 to 30, followed by a booster dose at month 12.

11. Hepatitis B vaccination.

• Vaccinate persons with any of the following indications and any person seeking protection from hepatitis B virus (HBV) infection:
  – sexually active persons who are not in a long-term, monogamous relationship (e.g., persons with more than 1 sex partner during the previous 6 months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or recent injection drug users; and men who have sex with men;
  – healthcare personnel and public safety workers who are potentially exposed to blood or other infectious body fluids;
  – persons with diabetes who are younger than age 60 years as soon as feasible after diagnosis; persons with diabetes who are age 60 years or older at the discretion of the treating clinician based on the likelihood of acquiring HBV infection, including the risk posed by an increased need for assisted blood glucose monitoring in long-term care facilities, the likelihood of experiencing chronic sequelae if infected with HBV, and the likelihood of immune response to vaccination;
  – persons with end-stage renal disease, including patients receiving hemodialysis, persons with HBV infection, and persons with chronic liver disease;
  – household contacts and sex partners of hepatitis B surface antigen-positive persons, clients and staff members of institutions for persons with developmental disabilities, and international travelers to countries with high or intermediate prevalence of chronic HBV infection; and
  – all adults in the following settings: STD treatment facilities, HIV testing and treatment facilities, facilities providing drug abuse treatment and prevention services, healthcare settings targeting services to injection drug users or men who have sex with men, correctional facilities, end-stage renal disease programs and facilities for chronic hemodialysis patients, and institutions and nonresidential day care facilities for persons with developmental disabilities.

• Administer missing doses to complete a 3-dose series of hepatitis B vaccine to those persons not vaccinated or not completely vaccinated. The second dose should be administered 1 month after the first dose; the third dose should be given at least 2 months after the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinstrix) is used, give 3 doses at 0, 1, and 5 months; alternatively, a 4-dose Twinstrix schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.

• Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B) administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.

12. Haemophilus influenzae type b (Hib) vaccination.

• One dose of Hib vaccine should be administered to persons who have anatomical or functional asplenia or sickle cell disease or are undergoing elective splenectomy if they have not previously received Hib vaccine. Hib vaccination 14 or more days before splenectomy is suggested.

• Recipients of hematopoietic stem cell transplant (HSCT) should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history; at least 4 weeks should separate doses.

• Hib vaccine is not recommended for adults with HIV infection since their risk for Hib infection is low.

13. Immunocompromising conditions.
Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, and inactivated influenza vaccine) and live vaccines generally are avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific conditions is available at www.cdc.gov/vaccines/hcp/acip-recs-index.html.

Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967. Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400. Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 8:00 a.m. – 8:00 p.m. Eastern Time, Monday – Friday, excluding holidays.